About
Aki Ko is the Chief Executive Officer, co-founder, and board chair of Elixirgen Therapeutics, a Baltimore clinical-stage biotech founded in 2017. He previously served as Chief Operating Officer of Elixirgen, LLC and President of Elixirgen Scientific, LLC. His public profile centers on advancing gene and mRNA therapies for rare diseases and aging-associated diseases, including telomere biology disorders and Duchenne muscular dystrophy.
Areas of interest
biotechrare diseasesaging-associated diseasesgene therapymRNA therapeuticstelomere biologystem cellsDuchenne muscular dystrophy